Cerebrolysin patent for CADASIL treatment
Summary
USPTO granted patent US12589118B2 to Ever Neuro Pharma GmbH for a method of using cerebrolysin to reduce mortality in patients with CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy). The patent includes 15 claims and was filed on August 28, 2018.
What changed
The USPTO granted patent US12589118B2 to Ever Neuro Pharma GmbH (inventors Stefan Winter and Herbert Mössler) covering the use of cerebrolysin preparations for prolonging the lifespan of CADASIL patients. The patent contains 15 claims and falls under CPC classifications including A61K 38/00, C07K 14/47, and A61P 25/28.
This patent grant is informational for pharmaceutical companies and healthcare providers researching or developing treatments for rare neurological conditions. No immediate compliance actions are required. Companies developing similar peptide-based treatments for vascular dementia or cerebrovascular diseases should review their Freedom to Operate positions to avoid potential infringement.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method of prolonging the lifespan of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) using a cerebrolysin® preparation
Grant US12589118B2 Kind: B2 Mar 31, 2026
Assignee
EVER NUERO PHARMA GMBH
Inventors
Stefan Winter, Herbert Mössler
Abstract
Disclosed is cerebrolysin for use in reducing mortality in CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy) patients.
CPC Classifications
A61K 38/00 A61K 38/1709 A61K 38/185 A61K 38/17 A61K 38/18 C07K 14/47 C07K 14/4705 C07K 14/475 C07K 14/48 A61P 25/28 A61P 25/00 A61P 9/00 A61P 9/10
Filing Date
2018-08-28
Application No.
16642307
Claims
15
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.